NewsRx

Search our medical news database

CryoLife, Inc.

Biosurgical device company presented results of SynerGraft arteriovenous device

Published in Physician Business Week, October 12th, 2004

CryoLife, Inc., (NYSE: CRY) announced that Chris Darby of the Oxford Transplant Center at Churchill Hospital in Oxford, U.K., presented positive results of the SynerGraft arteriovenous (AV) access device.

The results showed secondary patency of 83% and freedom of infection of 94% at 1 year in patients undergoing dialysis. These results were presented at the Advances in Tissue Engineering and Biology of Heart Valves Conference in Florence, Italy. CryoLife's SynerGraft AV access device, made of a bovine ureter, is only approved in Europe for dialysis patients.

Darby implanted the SynerGraft AV access device in 17 high-risk patients who failed previous...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Business Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook